• Clinical Trials

    Akaal Pharma has completed a Phase 1 clinical trial of its topical drug candidate AKP-11 for the treatment of patients with mild to moderate psoriasis. In this 4 week clinical study, AKP-11 was found to be safe, well tolerated and effective as a new topical therapy. The current available topical treatments suffer from various local and systemic adverse side effects including skin irritation, skin thinning and others.

    Read More
  • Partnering Opportunities

    Akaal Pharma is interested in exploring partnering opportunities with pharmaceuticals and biotech corporations for late-stage clinical development (Phase 2 and 3), regulatory approval and commercial launch of its internally designed, discovered and developed small molecule drug candidates for the treatment of various inflammatory and autoimmune diseases.

    Read More
  • Clinical Trials

    Akaal Pharma has completed a Phase 1 clinical trial of its topical drug candidate AKP-11 for the treatment of patients with mild to moderate psoriasis. In this 4 week clinical study, AKP-11 was found to be safe, well tolerated and effective as a new topical therapy. The current available topical treatments suffer from various local and systemic adverse side effects including skin irritation, skin thinning and others.

    Read More
  • Partnering Opportunities

    Akaal Pharma is interested in exploring partnering opportunities with pharmaceuticals and biotech corporations for late-stage clinical development (Phase 2 and 3), regulatory approval and commercial launch of its internally designed, discovered and developed small molecule drug candidates for the treatment of various inflammatory and autoimmune diseases.

    Read More

Sign Up For Our Newsletters

About Akaal Pharma

Akaal Pharma is a clinical-stage drug discovery and development company focused on developing breakthrough and innovative small molecule drugs for the treatment of autoimmune and inflammatory diseases. Akaal has created a pipeline of new topical and oral drugs for the treatment of dermatological diseases including Psoriasis and Atopic Dermatitis and autoimmune diseases including Multiple Sclerosis...

Read More

Pipeline

Akaal Pharma is developing novel, safer and highly effective drug candidates for the treatment of diseases with significantly large unmet medical need. Akaal Pharma's drug pipeline contains innovative new small molecule drugs for the treatment of Psoriasis, Atopic Dermatitis, Multiple Sclerosis (MS) and Ulcerative Colitis (UC). Akaal Pharma's business strategy is to partner its proprietary drug candidates...

Read More

Clinical Studies

Akaal Pharma has completed a Phase 1 clinical trial of its topical drug candidate AKP-11 for the treatment of patients with mild to moderate psoriasis. In this 4 week clinical study, AKP-11 was found to be safe, well tolerated and effective as a new topical therapy. The current available topical treatments suffer from various local and systemic adverse side effects including skin irritation, skin thinning and others. AKP-11 has shown superior profile as a topical therapy as it did not show any systemic exposure...

Read More